

HLA-associated COVID-19 Clinical Outcomes in the AllofUs Dataset


Grace J. Kim^{1, 2}*, Nayane dos Santos Brito Silva³, San Chu⁴, Judy S. Crabtree¹, Ronald W. Horswell⁴, Nicolas Vince³, Lucio Miele¹


PENNINGTON BIOMEDICAL RESEARCH CENTER


¹Department of Genetics, Louisiana State University Health Sciences Center, New Orleans, LA, United States ²School of Medicine, Louisiana State University Health Sciences Center, New Orleans, LA, United States ³Center for Research in Transplantation and Translational Immunology, Nantes Université, Nantes, Cedex, France ⁴Department of Population and Public Health, Pennington Biomedical Research Center, Baton Rouge, LA, United States



Immune genes (HLA) can help predict patients at greater risk of severe COVID-19 clinical outcomes, which can be used to advance precision medicine







significance threshold (p=0.05), while the red line delineates a Bonferroni-corrected threshold (p=0.05).



ACKNOWLEDGEMENT & FUNDING

Financial support was provided b NCATS T32, grant number 1T32TR004767, NCATS TL1, grant number 5TL1TR003106, and LA CaTS, grant number U54 GM104940. The All of Us Research Program is supported by the National Institutes of Health, Office of the Director: Regional Medical Centers: 1 OT2 OD026554; 1 OT2 OD026554; 1 OT2 OD026556; 1 OT2 OD026550; 1 OT2 OD026552; 1 OT2 OD026553; 1 OT2 OD026548; 1 OT2 OD026551; 1 OT2 OD026555; IAA #: AOD 16037; Federally Qualified Health Center: 5 U2C OD023196; Biobank: 1 U24 OD023121; The Participant Center: U24 OD023176; Participant Technology Systems Center: 1 U24 OD023206; and Community Partners: 1 OT2 OD023206; and Community Partner the All of Us Research Program would not be possible without the partnership of its participants.

Created with BioRender Poster Builder